Encompass Health Corporation (NYSE:EHC) Q3 2023 Earnings Call Transcript

Encompass Health Corporation (NYSE:EHC) Q3 2023 Earnings Call Transcript October 27, 2023

Operator: Good morning, everyone and welcome to Encompass Health’s Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Today’s conference call is being recorded. If you have any objections, you may disconnect at this time. I will now turn the call over to Mark Miller, Encompass Health’s Chief Investor Relations Officer. Please go ahead.

Mark Miller: Thank you, operator, and good morning, everyone. Thank you for joining Encompass Health’s Third Quarter 2023 Earnings Call. Before we begin, if you do not already have a copy, the third quarter earnings release, supplemental information and — our website at encompasshealth.com. On Page 2 of the supplemental information, you will find the safe harbor statements, which are also set forth in greater detail on the last page of the earnings release. During the call, we will make forward-looking statements, which are subject to risks and uncertainties, many of which are beyond our control. Certain risks and uncertainties and like those relating to regulatory developments as well as volume, bad debt and labor cost trends that could cause actual results to differ materially from our projections, estimates and expectations are discussed in the company’s SEC filings included in the earnings release and related Form 8-K, the Form 10-K for the year ended December 31, 2022, and the Form 10-Q for the quarters ended March 31, 2023, June 30, 2023, and September 30, 2023, when filed.

We encourage you to read them. You are cautioned not to place undue reliance on the estimates, projections, guidance and other forward-looking information presented, which are based on current estimates of future events and speak only as of today. We do not undertake a duty to update these forward-looking statements. Our supplemental information and discussion on this call will include certain non-GAAP financial measures. For such measures, reconciliation to the most directly comparable GAAP measure is available at the end of the supplemental information at the end of the earnings release and as part of the Form 8-K filed yesterday with the SEC, all of which are available on our website. I would like to remind you that we will adhere to the 1 question and 1 follow-up question rule to allow everyone to submit a question.

If you have additional questions, please feel free to put yourself back in the queue. With that, I’ll turn the call over to Mark Tarr, Encompass Health’s President and Chief Executive Officer.

Mark Tarr: Thank you, Mark, and good morning, everyone. We’re very pleased with our third quarter results, driven by continued strong volume growth and a substantial year-over-year reduction in premium labor costs. Our third quarter revenues increased 10.8% and adjusted EBITDA increased 21.6%. Q3 total discharges increased 7.3%, with same-store discharges up 4.3%. Our strong volume growth continues to underscore our value proposition to referral sources, payers and patients. Our patient acuity continues to broaden with more normalized patient flows through the health care system. Surcharges were up 5.8% year-over-year, while knee and hip replacement and fracture of the lower extremity discharges grew approximately 14% in the aggregate year-over-year though of a relatively small base.

Given the strong demand for inpatient rehabilitation services, we have continued to invest in capacity additions. We opened one 40-bed de novo in the third quarter, bringing us to 6 de novos year-to-date. We also added 26 beds to existing hospitals in the third quarter for total capacity additions of 340 beds over the first 9 months of 2023. Based on favorable weather conditions and construction efficiencies, we are accelerating the opening of our Fitchburg, Wisconsin hospital from first quarter of 2024 to fourth quarter of 2023. As a result, we now plan to open 2 de novos in Q4 and add 5 beds to existing hospitals, resulting in a total of 441 beds for the year. Three of our bed addition projects originally scheduled for 2023 have shifted to 2024 due in each case to local permitting issues.

As a result of this shift, we have to add more than 150 beds to existing hospitals in 2024. We continue to build and maintain an active pipeline of de novo projects both wholly owned and JVs with acute care hospitals. We currently have announced 18 de novos with opening dates beyond 2023. During Q3, we again met the increasing demand for our services while reducing contract labor and sign-on and shift bonus expenditures. Contract labor was down approximately $6 million or 24% from Q3 of 2022 while sign-on and ship bonuses decreased approximately $10 million or 41% from Q3 of 2022. For the second consecutive quarter, our talent acquisition efforts resulted in over 200 net same-store RM hires. Please be mindful that hiring results may vary significantly from quarter-to-quarter based on seasonality and other factors.

Review Choice Demonstration, or RCD, began on August 21 in Alabama. Recall that under RCD, every claim is reviewed for documentation and medical necessity. We elected pre-claim review, as we believe it allows for a more iterative process and the potential for real-time adjustments. Our results thus far are encouraging. The affirmation rate target set by CMS under RCD is 80% of claims submitted during the first 6 months and our affirmation rate is well above that. Given our Q3 results and expectations for Q4, we are updating our 2023 guidance to include net operating revenue of $4.77 billion to $4.8 billion, adjusted EBITDA of $940 million to $955 million and adjusted earnings per share of $3.41 to $3.52. The key considerations underlying our guidance can be found on Page 12 of the supplemental slides.

Now with that, I’ll turn it over to Doug for further color.

Doug Coltharp: Thanks, Mark, and good morning, everyone. As Mark stated, we are very pleased with our Q3 results. We continue to see significant improvement and year-over-year premium labor costs. Our Q3 contract labor plus sign-on and ship bonuses of $33.3 million was comprised of approximately $18.9 million in contract labor and $14.4 million in sign-on and ship bonuses. This compares favorably to $24.8 million in contract labor and $24.2 million in sign-on and ship bonuses in Q3 last year. Contract labor utilization declined year-over-year and sequentially. Q3 contract labor FTEs of 388 represented a 19% decline from Q3 ’22, and an 18% decline from Q2 of ’23. Contract labor FTEs as a percent of total FTEs was 1.5%, a 40 basis point decline from Q3 ’22 and a 30 basis point decline sequentially.

Agency rates declined year-over-year and were up modestly sequentially. Our Q3 ’23 agency rate for FTE was approximately $192,700, down from approximately $204,600 in Q3 ’22. I’ll remind you that rates are impacted by the license level of the clinician utilized as well as by geographic specific market conditions. Sign-on and shift bonuses decreased $9.8 million or 41% from Q3 ’22 and were roughly flat sequentially. As we consider contract labor and shift bonuses for Q4, it is worth noting that holiday coverage typically requires premium pay rates. Partially offsetting the benefit of lower premium labor costs in Q3 was an increase in our internal SW per FTE rate. This rate, which excludes contract labor and sign-on and shift bonuses increased 6% over Q3 ’22, similar to the level of increase we saw in Q2.

The increase was attributable to proactive market adjustments primarily for nurses, higher compensation for new hires and planned merit increases. These actions are contributing to our success in new hiring and improvement in turnover. Our updated guidance assumes a continuation of this trend in Q4. In line with expectations, EPOB for the quarter was 3.41, an increase from 3.39 in Q3 ’22 and from 3.38 in Q2 ’23. Revenue reserves related to bad debt increased 20 basis points to 2.2% as a result of write-offs of older claims denied by the Departmental Appeals Board, which we have elected not to appeal the Federal District Court. Our de novo embedded edition strategy continues to generate solid growth and contribute to share gains. Our de novo has performed exceptionally well in Q3, contributing $900,000 in adjusted EBITDA.

This brings year-to-date net preopening and ramp-up costs to $7.6 million. We still expect full year preopening and ramp-up costs to be $10 million to $12 million due to the opening of 2 hospitals in Q4 and the cost we expect to incur in Q4 for hospitals scheduled to open in the first half of 2024. As can be seen on Page 14 of the supplemental information, the acceleration of our Fitchburg opening into 2023 and the progress on a number of pipeline projects scheduled for 2024 and 2025, has led to an upward revision of our 2023 de novo capital expenditures estimate to $315 million to $325 million. Year-to-date adjusted free cash flow of $432.2 million represented a 47% increase from the first 9 months of 2022. As can be seen on Page 13 of the supplemental information, we have updated our assumptions for certain cash flow items, contributing to an increase in our 2023 adjusted free cash flow estimate to $445 million to $500 million.

Finally, we ended Q3 with a net leverage ratio of 2.8x, down from 3.4x at the end of 2022. Our balance sheet and liquidity remain well positioned. With that, we’ll open the lines for Q&A.

See also 20 States with the Highest Alcohol and Beer Tax and 15 Easiest Smartphones to Use for Seniors and the Elderly.

Q&A Session

Operator: At this time, we will open the floor for questions. [Operator Instructions] We ask that you limit yourself to 1 question and 1 follow-up question. Our first question will come from Kevin Fischbeck with Bank of America.

Kevin Fischbeck : So I guess I would like to ask about labor. Obviously, a lot of progress on contract labor expense and sign-on bonuses. But overall, the wage outlook has gone up, and now we’ve seen sequentially contract labor wage has gone up for a couple of quarters now. I mean, how would you characterize the overall labor market today, and how do you think about the ability to — if this year, you had the benefit of contract labor coming down, how do you think about the ability to manage through labor pressure into next year?

Mark Tarr: Kevin, this is Mark. As you know, we’ve made really nice progress on the contract labor side and the premium pay categories. I would characterize it is still a very tight market out there. Certain markets are a little bit more challenging than others to find staff. We’ve done a really nice job in terms of our recruitment of RNs, which is the most challenging segment of our staffing base at this point. But I think we put systems in place and have the initiatives at our hospitals to be successful going into next year, and competing very strong and this really tight market.

Doug Coltharp: Yes. Just to add a couple of things to that, Kevin. First of all, I think what you’re seeing in terms of the sequential increase in rates has more to do with the fact that as we reduce our reliance on contract labor, what we’re seeing is more of a concentration at higher license levels and in those geographies that are more expensive and where it’s a little bit tighter. So some of that is kind of self-filling. As we look to 2024, from a premium labor perspective, we think that it’s either going to be stable or improving further. We’ve been successful in getting the contract labors, FTEs down to 1.5%. That’s not where we were pre-pandemic, which was just under 1%. Do we think that there’s an opportunity for further progress?

Yes, but a minimum, we don’t see that kicking back up above that. Then we also think that with regard to the 6% increase in SW per FTE that we’ve been running this year, evidence of the fact that we’ve been able to hire 404 — or 402 net new RNs in each of the last 2 quarters, we believe that we’ve hit the right level — excuse me, that was over the last 2 quarters, cumulative. We believe that we’ve hit the right level in terms of being able to procure that new talent and our turnover has been reduced as well. And as a result of those factors, we don’t think that we’re going to have to anniversary another 6% on top of the 6% this year. We would expect labor inflation to moderate considerably next year.

Kevin Fischbeck : Okay. That’s helpful. And then, I guess, as far as volumes go, there’s been a lot of talk about seasonality — normal seasonality. I guess, where do you think that you are in the industry is as far as IRF volumes? Are we back to kind of normal and normalish growth from here? Is there any pent-up demand? How are you thinking about this as a base for future growth but also seasonality?

Mark Tarr: Kevin, we’ve commented in past quarters, and I think that, that holds true now is that the pandemic gave IRF a real chance to show the difference in post-acute settings. And I believe that we have continued to take market share from skilled nursing facilities or other areas that otherwise may have taken similar types of patients. And so I think we’re well positioned going forward to continue to provide value to referral sources and the payers.

Doug Coltharp: As you think about our discharge growth for the second half of this year, of course, Q3 we just reported, recall that we are up against more challenging comps from last year. In the back half of last year, total discharge growth was running north of 7% with more than 4% of that coming from same store. And so we really felt like the seasonal patterns started to reestablish themselves in the second half of this year. And it feels like that is continuing this year. With regard to pent-up demand, there’s no doubt that we are seeing an increased flow of some of those lower acuity hip and knee replacements that Mark described, what’s offsetting some of that is a reduction in COVID patients. And so the demand that we’re seeing in those categories is actually probably a little bit higher than might otherwise show through into the total discharges. But generally speaking, it feels like we’re kind of back into our traditional seasonal flows.

Operator: Our next question will come A.J. Rice with UBS.

A.J. Rice : First question was more technical. You’re highlighting this $3.5 million write-off of the de novo project. I don’t know if there’s any background on that is sort of unusual for you not to move forward with one. But — I mean my main point on that is you’ve updated the guidance. It looks like you’re including that so that the actual underlying increase in operating results is a little more than on the surface might include, but I want to just confirm that.

Doug Coltharp: And A.J., I’m sorry, we didn’t make that more clear in our materials. That write-off is below the adjusted EBITDA line. And you’re right, it’s less unusual in terms of the fact that we’re deciding not to press forward with a de novo project and more unusual in terms of its scope. We’re managing an active pipeline of approximately 50 projects and then what you don’t necessarily see is there are about 20 behind that, that are in what we ineloquently describe as exploratory mode. We will from time to time than we have in the past have a project that for various reasons, sometimes it’s getting hung up in the CON process, will elect not to move forward with. In almost all instances, those items are less than $1 million.

We had one that was approximately $1 million. It was actually included in 3. What was unusual about this project is that we had gotten further along. It’s the project in the Midwest. It was with an existing joint venture partner. We had acquired some land. We were actually doing some of the site work. And unfortunately, every time we refined our estimate for the cost to build this facility it was getting worse and worse in a way that we weren’t able to use some of the other offsets we’ve effectively used on other projects. In addition to that, this was a particular market where the labor market conditions were moving in an adverse direction as well. So we had some difficult talks with our joint venture partner, but ultimately, we concluded together that it did not make sense to press forward at this time and so we took the write-off.

I really view that as an anomaly given its size because it’s unusual for us to get that far down the path before we make that kind of decision. I don’t think it speaks to any lack of enthusiasm with regard to our continuing development pipeline, I do think it highlights the fact that we are disciplined in our approach.